Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUATRO: Cabotegravir ultra long-acting plus rilpivirine ultra long-acting vs cabotegravir long-acting plus rilpivirine long-acting in virologically suppressed HIV-1
jRCT2031260242Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by GSK. Primary endpoint: Percentage of participants with plasma HIV-RNA >= 50 copies/mL at Month 11 (FDA Snapshot). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cabotegravirrilpivirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2031260242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260242.